Technology
Health
Pharmaceutical

AC Immune

$4.80
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.26 (5.78%) Today
+$0.04 (0.84%) After Hours

Why Robinhood?

You can buy or sell AC Immune and other stocks, options, ETFs, and crypto commission-free!

About

AC Immune SA Common Stock, also called AC Immune, is a clinical stage biopharmaceutical company, which engages in developing therapeutic and diagnostic products. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Read More The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.

Employees
Headquarters
Lausanne, Basel-Landschaft (Basle Country)
Founded
2003
Market Cap
320.65M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
256.18K
High Today
$5.20
Low Today
$4.52
Open Price
$4.52
Volume
917.62K
52 Week High
$17.40
52 Week Low
$3.25

Collections

Technology
Health
Pharmaceutical
Top Movers
Medical
Biopharmaceutical
2016 IPO
Europe (Non-UK)

News

Simply Wall StMar 13

Such Is Life: How AC Immune (NASDAQ:ACIU) Shareholders Saw Their Shares Drop 60%

AC Immune SA (NASDAQ:ACIU) shareholders should be happy to see the share price up 19% in the last month. But that isn’t much consolation to those who have suffered through the declines of the last year. Like an arid lake in a warming world, shareholder value has evaporated, with the share price down 60% in that time. So the bounce should be viewed in that context. Arguably, the fall was overdone. See our latest analysis for AC Immune AC Immune isn’t currently profitable, so most analysts would look to rev...

1,517
MarketBeatMar 8

Stock Price, News, & Analysis for AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding.

278

Earnings

-$0.25
-$0.05
$0.15
$0.35
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
$0.35 per share
Actual
Available Mar 21, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.